Hepatitis A

Havrix Cleared for Preventing HAV in Chronic Liver Disease Patients

Published in Vaccine Weekly, July 7th, 1997

SmithKline Beecham, Philadelphia, Pennsylvania, distributor of Havrix (Hepatitis A Vaccine, Inactivated), announced that it has received U.S. Food and Drug Administration (FDA) clearance to expand the license for Havrix to include prevention of hepatitis A in persons with chronic liver disease.

Havrix is the only vaccine specifically licensed for active immunization against the hepatitis A virus in chronic liver disease patients. It is estimated that more than 5 million Americans are currently living with one or more of the diseases collectively classified as chronic liver disease, including alcoholic cirrhosis, chronic hepatitis B, chronic hepatitis C, autoimmune...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry